PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?

Giuseppe Montalto, Manfredi Rizzo, Banach, M; Obradović, M; Rysz, J; Mikhailidis, Dp; Isenović, Er.

    Risultato della ricerca: Articlepeer review

    55 Citazioni (Scopus)


    Plasma low-density lipoprotein cholesterol (LDL-C) is one of the biomarkers of cardiovascular disease (CVD) risk. LDL is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation of the LDLR. PCSK9 inhibition is attractive as a new strategy for lowering LDL-C levels, especially in combination with lipid lowering drugs such as statins. We review data from the available studies which focus on PCSK9 as a potential target in the treatment of hyperlipidemia. Further studies are still necessary to investigate the potential underlying mechanisms involved
    Lingua originaleEnglish
    pagine (da-a)3869-3877
    Numero di pagine9
    RivistaCurrent Pharmaceutical Design
    Stato di pubblicazionePublished - 2013


    Entra nei temi di ricerca di 'PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?'. Insieme formano una fingerprint unica.

    Cita questo